Oncolytic adenovirus based on serotype 3. (Q39616158)

13 September 2017

Oncolytic adenovirus based on serotype 3. (English)

1 reference

13 September 2017

1 reference

1 reference

O Hemminki

1

1 reference

13 September 2017

G Bauerschmitz

2

1 reference

13 September 2017

S Hemmi

3

1 reference

13 September 2017

S Lavilla-Alonso

4

1 reference

13 September 2017

I Diaconu

5

1 reference

13 September 2017

K Guse

6

1 reference

13 September 2017

A Koski

7

1 reference

13 September 2017

R A Desmond

8

1 reference

13 September 2017

M Lappalainen

9

1 reference

13 September 2017

A Kanerva

10

1 reference

13 September 2017

V Cerullo

11

1 reference

13 September 2017

S Pesonen

12

1 reference

13 September 2017

A Hemminki

13

1 reference

13 September 2017

24 December 2010

1 reference

13 September 2017

1 reference

13 September 2017

18

1 reference

13 September 2017

4

1 reference

13 September 2017

288-296

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2010.79

13 September 2017

0 references

cites work

Oncolytic viruses in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Cancer selective adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Oncolytic adenoviruses for cancer gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Directed evolution generates a novel oncolytic virus for the treatment of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

The nucleotide sequence and a first generation gene transfer vector of species B human adenovirus serotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification: Incorporation of RGD Peptide or Ad5/3 Chimerism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Current developments in adenovirus-based cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Tissue-specific promoters active in CD44+CD24-/low breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Modified adenoviruses for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

inferred from DOI database lookup

7 January 2021

based on heuristic

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.79

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2010.79

1 reference

13 September 2017

1 reference